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Helicobacter pylori infections are one of the major issues that produce gastric and duodenal ulcers due to chronic 
gastritis. Deforestation and global warming may cause ecological imbalance followed by climatic change due to enhanced 
temperature. This may contribute to abdominal discomfort and gastritis specifically in case of in taking a lot of non-
vegetables, fast and junk foods, oily and spicy foods. H. pylori, which is asymptomatic for almost 80% of people’s 
gastrointestinal tract (G.I.T.), may be stimulated due to chronic gastritis. It has been associated with colorectal polyps and 
cancer, if not treated well. Therefore, attention has been paid to predict some urea compounds as H. pylori antagonists 
utilizing structure-based molecular docking. Earlier reports of such work do not exist. 
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Helicobacter pylori infection is a major health 
concern worldwide. Helicobacter pylori is a Gram-
negative, microaerophilic bacterium having the ability 
to colonize and it can grow in human gastric epithelial 
tissue and mucus. It can cause peptic ulcers, duodenal 
ulcers, and chronic gastritis and it is also involved in 
the development of gastric cancer1. Marshall BJ  
and Warren JR have identified H. pylori in 19842.  
10 years later, the International Agency for Research 
on Cancers classified H. pylori as carcinogenic to 
humans3. The acid environment of the stomach is 
crucial for H. pylori to survive in the presence of  
urea. H. pylori cannot survive in the normal 
environment of the stomach in the presence of urea 
because of the subsequent increase in pH rather than 
ammonia toxicity. H. pylori N6 strain survived well  
in solutions with pH values ranging from 4.5 to 7.0 in 
the absence of urea4 but At low pH values (e.g. 3.5), 
the addition of urea increases survival5. There are four 
chemoreceptor genes (tlpA, tlpB, tlpC, and tlpD) 
expressed in H. pylori strain SS1 and strain KE26695. 
Matthew A and co-workers experimentally found  
that tlpA, tlpC, and tlpD mutants colonize mice to 
near wild-type levels whereas tlpB mutants were 
defective for colonization of highly permissive 
C57BL/6 interleukin-12 (IL-12) (p40−/−)-deficient 
mice. pH taxis, like motility and urease activity, is 
crucial for colonization and insistence in the gastric 
mucosa, and thus TlpB function might represent a 
novel target for the inhibition of h. pylori bacterium6. 
Sweeney EG and co-workers were experimentally 
found that urea and the urea binding site residues  
of H.pylori chemo-receptor TlpB play critical roles  
in the ability of H. pylori to measure the acid 
concentration. The signaling model predicts that 
protonation events at Asp114, affected by changes  
in pH, dictate the stability of TlpB through urea 
binding7. 
Therefore it was postulated that urea derivatives 
may act as a competitive inhibitor of H. pylori 
chemoreceptor TlpB. It is also important to note that 
there is no direct inhibitor of H. pylori TlpB studied 
yet. Therefore in the present study, we have attempted 
to search urea compounds utilizing PubMed, 
PubChem, Sigma-Aldrich, HMDM, Wikipedia, 
chemical book, etc. These compounds have been 
docked and the mode of binding in term of interacting 
residues was analyzed in comparison to urea 
hydroxyurea and acetamide which are shown as 
agonist because these ligands interacting with 
ASP114, responsible for protonation where 
stabilization of TlpB. Hence in quest of urea 
derivatives which are may interact with H. pylori 
TlpB active cavity having a lack of interaction with 




ASP114 may become an antagonist. These have been 
performed in the present study utilizing structure-
based molecular docking. 
 
Materials and Methods 
Many 38 urea derivatives were obtained from Pub 
Chem, Sigma-Aldrich databases and several kinds of 
literature. The chemical structures of these derivatives 
were drawn utilizing 2D ChemDraw. 2D structures 
were transformed into 3D views which were fully 
optimized considering Marck molecule force field 
(MMFF) using a value of 0.01 as dielectric constant 
using chem3D ultra for making them energetically 
stable8. The crystal structure of H. pylori 
chemoreceptor TlpB (PDB ID: 3UB6) co-crystallized 
with urea was selected as the receptor for the docking 
studies7. Molecular docking helps to study interactions 
between ligand and receptor to identify active binding 
residues of target proteins. It helps to obtain the best 
geometry of ligand-receptor complex so that the energy 
of interaction between ligand and receptor is minimum.  
 
The minimum energy of interaction is called a score 
represented by different scoring functions. The ligand 
with minimal score could be screened as potential 
bioactive lead having a maximal affinity towards 
receptor, yielding a relative rank ordering of the 
docked compounds with respect to affinity. Prediction 
of affinity is referred to as scoring9-11. 
The protein was downloaded from the Brookhaven 
protein data bank12. The downloaded protein was 
prepared by removing all water molecules and 
hydrogen atoms in the H-depleted target molecule 
were added. All the optimized ligands (Table I) were 
docked into the active binding cavity of H. pylori 
chemoreceptor TlpB target gene using Argus Lab 
4.0.1 freeware13, 14. The co-crystal urea was taken as 
reference for creating the ligand binding site 
considering grid resolution (angle) of 0.4 degrees as 
default value. ArgusLab allows free rotation of the 




Table I — Urea compounds along with their mode of interactions in the cavity of H. pylori chemo-receptor TlpB 
Compd Compd Name Compd Structure CAS Number Mode of interaction Docking scores 
(kcal/mol) 
Predicted nature 
of the ligand 
Crystal structure analysis of  H. pylori chemo-receptor TlpB 
1 Urea O
H2N NH2  
57-13-6 LYS116, TYR153, 
ASP114, TYR140 





127-07-1 LYS116, TYR153, 
ASP114, TYR185 
-6.257 Full agonist 
3 Acetamide O
H2N CH3  
60-35-5 LYS116, TYR153, 
ASP114 
-5.627 Partial agonist 














-7.275 Partial agonist 
5 Ammonium 














-6.265 Partial agonist 
(Contd.)
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-6.386 Partial agonist 
15 Ethyl carbamate O
O NH2  




-6.601 Partial agonist 
(Contd.)
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-5.970 Partial agonist 
(Contd.)
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-5.99 Partial agonist 
32 Thiourea S





























-6.370 Partial agonist 
(Contd.)
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of the ligand 
Urea compounds docked against H. pylori chemo-receptor TlpB 














-5.163 Full antagonist 
36 Guanidine NH





























-5.666 Full antagonist 
 
Results and Discussion 
The best complex pose with minimal interaction 
energy has been taken into consideration for a better 
explanation of the mode of interaction between the 
ligand and active amino acid residues of the receptor 
protein. 
The present investigation deals with the docking of 
38 urea derivatives with H. pylori chemoreceptor 
TlpB. The detailed results of interactions are given in 
Table I. Docked complexes provide an insight into the 
activity patterns of various 38 urea derivatives in 
terms of hydrogen-bond, sulfur-bond, and 
hydrophobic interactions.  
Molecular docking of 38 urea derivatives was carried 
out to predict its agonistic and antagonistic activity. 
Urea, hydroxyurea, and acetamide, were co-crystallized 
with TlpB (PDB IDs: 3UB6, 3UB9, 3UB7). It was 
shown that urea produces H-bond interactions with 
LYS116, TYR153, TYR140, and ASP114. 
Hydroxyurea produces the same mode of binding 
whereas acetamide does not interact with TYR140 
because of possessing a methyl group. Carbonyl group 
of urea, hydroxyurea, and acetamide produce H-bonding 
with LYS116 while both amino groups produce  
H-bonding with ASP114 where one amino is also 
produced H-bonding with TYR140. Methyl group 
present in acetamide does not produce any interaction 
which is shown in Figure 1, Figure 2 and Figure 3. 
It was reported that urea is an agonist. As the mode 
of binding of hydroxyurea is similar to that of urea, 
the hydroxyurea may also act as agonist whereas 
acetamide may categorize as a partial agonist. 
Compounds 4-34 may interact with LYS116 and 
ASP114 which are common amino acids for partial 
agonist hydroxyurea. Therefore these compounds may 
be placed in the category of partial agonist. 
 
 
Figure 1 — Agonistic interaction between ligand (Urea) and 
H. pylori TlpB. 
 




Compounds no. 35-38 enter into the same cavity of 
TlpB and may produce antagonistic activity because 
they do not capture ASP114 which is crucial for pH 
sensing long life of H. pylori. Compound no. 35 
produces H-bond interaction with ASN117, LYS154, 
SER130, and VAL131 while hydrophobic interaction 
with MET115 and TYR16. Compound no. 36 
produces H-bond interaction with LYS157, MET102, 
and TYR185. Compound no. 37 produces H-bond 
interaction with ASN117 and GLN129 while 
hydrophobic interaction with PRO156, PRO163, 
TYR136, VAL131 and S-bonding with MET155. 
Compound no. 38 produces H-bond interaction with 
LYS116, TY153, TYR185 and PRO156 showing in 
Figure 4, Figure 5, Figure 6 and Figure 7. 
 
 
Figure 2 — Partial-agonistic interaction between ligand




Figure 3 — Partial-agonistic interaction between ligand
(Acetamide) and H. pylori TlpB. 
 
 
Figure 4 — Antagonistic interaction between ligand (DMDM 




Figure 5 — Antagonistic interaction between ligand (Guanidine) 




Figure 6 — Antagonistic interaction between ligand (Monuron) 
and H. pylori TlpB. 





ASP114 is pH sensing amino acid which helps for 
H. pylori life in GIT. Compound numbers 35-38 when 
docked with H. pylori TlpB cavity, it causes the 
breakdown of ASP114 amino acid from the active 
binding site. Therefore these compounds may act as 
an antagonist. Compound numbers 3-34 show mode 
of binding similarity with urea. The captured amino 
acids are LYS116, ASP114, TYR140, TYR153, 
MET102, THR183. Therefore these compounds may 
become partial agonist and may potentiate H. pylori 
life in GIT. The binding energy range of agonist is -
6.257 to -5.123 Kcal/mol. The binding energy range 
of full antagonist is -6.206 to -5.124 Kcal/mol. 
Therefore it is concluded that the full antagonist such 
as DMDM hydantoin, Guanidine, Monuron, and  
N-ethyl-N-hydroxyurea may produce competitive 
inhibition of target H. pylori TlpB cavity because they 
produce similarity in mode of binding as well as the 
energy of interaction. 
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Figure 7 — Antagonistic interaction between ligand (N-ethyl-N-
hydroxyurea) and H. pylori TlpB. 
 
